Parallax Volatility Advisers
KYNB

Parallax Volatility Advisers’s Kyntra Bio KYNB Stock Holding History

Parallax Volatility Advisers’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,948
Closed -$2.63M – 3130
2021
Q2 		$2.63M Buy
+3,948
New +$2.27M ﹤0.01% 1525

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GC
GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

Parallax Volatility Advisers's KYNB Position: Q3 2021 in Review

Parallax Volatility Advisers sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 1,013 shares — an estimated $674K sold.

Parallax Volatility Advisers first reported a position in KYNB in Q4 2017 and held it in 5 quarters. The position peaked at $4.12M in Q2 2018. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

  • Parallax Volatility Advisers reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,013 Kyntra Bio shares in Q3 2021, an estimated $674K.
  • Parallax Volatility Advisers first reported a position in Kyntra Bio in Q4 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Kyntra Bio position peaked at $4.12M in Q2 2018.
  • 164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on Parallax Volatility Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.